Abstract
Neurosarcoidosis is an uncommon but potentially serious manifestation of sarcoidosis. While the cranial nerves are most frequently affected, neurosarcoidosis can involve other nervous system tissues including the meninges, brain parenchyma (especially the hypothalamic region), spinal cord, peripheral nerve, and muscle. Diagnosis may be particularly challenging when neurosarcoidosis occurs in isolation. Diagnostic criteria usually include histologic identification of a noncaseating granuloma, supportive laboratory or imaging tests or both, and a compatible clinical course. Treatment has not been subjected to rigorous study, but corticosteroids are typically the first line of therapy and approximately half of patients have substantial benefit. For patients who are refractory to or intolerant of corticosteroid therapy, second-line agents include azathioprine, methotrexate, cyclosporine, cyclophosphamide, mycophenolate, and even cranial irradiation. The combination of infliximab and mycophenolate mofetil is under study as well. Treatment options will likely evolve as well-designed studies are undertaken.
Keywords: Neurosarcoidosis, sarcoidosis, cranial neuropathy, meningitis, neuroendocrine dysfunction, seizures, peripheral neuropathy, myopathy
Current Neuropharmacology
Title: Neurosarcoidosis
Volume: 9 Issue: 3
Author(s): David Lacomis
Affiliation:
Keywords: Neurosarcoidosis, sarcoidosis, cranial neuropathy, meningitis, neuroendocrine dysfunction, seizures, peripheral neuropathy, myopathy
Abstract: Neurosarcoidosis is an uncommon but potentially serious manifestation of sarcoidosis. While the cranial nerves are most frequently affected, neurosarcoidosis can involve other nervous system tissues including the meninges, brain parenchyma (especially the hypothalamic region), spinal cord, peripheral nerve, and muscle. Diagnosis may be particularly challenging when neurosarcoidosis occurs in isolation. Diagnostic criteria usually include histologic identification of a noncaseating granuloma, supportive laboratory or imaging tests or both, and a compatible clinical course. Treatment has not been subjected to rigorous study, but corticosteroids are typically the first line of therapy and approximately half of patients have substantial benefit. For patients who are refractory to or intolerant of corticosteroid therapy, second-line agents include azathioprine, methotrexate, cyclosporine, cyclophosphamide, mycophenolate, and even cranial irradiation. The combination of infliximab and mycophenolate mofetil is under study as well. Treatment options will likely evolve as well-designed studies are undertaken.
Export Options
About this article
Cite this article as:
Lacomis David, Neurosarcoidosis, Current Neuropharmacology 2011; 9 (3) . https://dx.doi.org/10.2174/157015911796557975
DOI https://dx.doi.org/10.2174/157015911796557975 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
An Unusual Case of Reversible Empty Sella
Endocrine, Metabolic & Immune Disorders - Drug Targets The Neuroinflammatory Response in Plaques and Amyloid Angiopathy in Alzheimers Disease: Therapeutic Implications
Current Drug Targets - CNS & Neurological Disorders Distribution of Iron Uptake Systems Encoding Genes Among the Clinical Isolates of Escherichia coli Compared to Foodstuffs Isolates
Infectious Disorders - Drug Targets The Extracellular Bacterial HtrA Proteins as Potential Therapeutic Targets and Vaccine Candidates
Current Medicinal Chemistry Therapeutic Options for the Treatment of 2019-Novel Coronavirus in India: A Review
Coronaviruses Inhibitors of Catechol-O-methyltransferase in the Treatment of Neurological Disorders
Central Nervous System Agents in Medicinal Chemistry Microsomal Prostaglandin E Synthase: A Key Enzyme in PGE2 Biosynthesis and Inflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Clinical Implications of Recent Insights into the Structural Biology of Beta2 Adrenoceptors
Current Drug Targets Perspectives and New Aspects of Metalloproteinases’ Inhibitors in the Therapy of CNS Disorders: From Chemistry to Medicine
Current Medicinal Chemistry 5HT1F- and 5HT7-Receptor Agonists for the Treatment of Migraines
CNS & Neurological Disorders - Drug Targets Intracranial Non-traumatic Aneurysms in Children and Adolescents
Current Pediatric Reviews CNS Drug Delivery Systems: Novel Approaches
Recent Patents on Drug Delivery & Formulation <i>Nigella sativa</i> – A Functional Spice From A Pharaoh’s Tomb to Modern Healthcare
The Natural Products Journal New Chemotherapy and Immunotherapy for Tuberculosis
Current Respiratory Medicine Reviews Coumarins as Inhibitors of HIV Reverse Transcriptase
Current HIV Research Drug Therapy of Neuropathic Pain: Current Developments and Future Perspectives
Current Drug Targets Novel Kynurenic Acid Analogues in the Treatment of Migraine and Neurodegenerative Disorders: Preclinical Studies and Pharmaceutical Design
Current Pharmaceutical Design Development and Validation of Microbiological Assay for Ceftriaxone and its Application in Photo-stability Study
Current Pharmaceutical Analysis Embryonic Stem Cell-Based Screen for Small Molecules: Cluster Analysis Reveals Four Response Patterns in Developing Neural Cells
Current Medicinal Chemistry Design of Lipophilic Prodrugs to Improve Drug Delivery and Efficacy
Current Drug Targets